Phase 1, Randomized Open Label, Multiple Dose, Parallel Study To Assess The Immunogenicity Of Multiple Subcutaneous (sc) Doses Of The Proposed Pegfilgrastim Biosimilar (Pf-06881894) And Us-approved Neulasta (Registered) In Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 13 Jul 2018
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Febrile neutropenia; Neutropenia
- Focus Pharmacodynamics
- Sponsors Pfizer
- 03 Jul 2018 Planned End Date changed from 29 Jul 2018 to 25 Jul 2018.
- 03 Jul 2018 Planned primary completion date changed from 29 Jul 2018 to 25 Jul 2018.
- 06 Apr 2018 Planned End Date changed from 25 Jun 2018 to 29 Jul 2018.